Han Songyan, Bourdon Alice, Hamou Wissam, Dziedzic Noelle, Goldman Orit, Gouon-Evans Valerie
Department of Developmental and Regenerative Biology, Black Family Stem Cell Institute, Mount Sinai School of Medicine, New York, New York, USA.
J Stem Cell Res Ther. 2012 Aug 15;Suppl 10(8):1-7. doi: 10.4172/2157-7633.S10-008.
Liver diseases affect millions of people worldwide, especially in developing country. According to the American Liver Foundation, nearly 1 in every 10 Americans suffers from some form of liver disease. Even though, the liver has great ability to self-repair, in end-stage liver diseases including fibrosis, cirrhosis, and liver cancer induced by viral hepatitis and drugs, the liver regenerative capacity is exhausted. The only successful treatment for chronic liver failure is the whole liver transplantation. More recently, some clinical trials using hepatocyte transplantation have shown some clinical improvement for metabolic liver diseases and acute liver failure. However, the shortage of donor livers remains a life-threatening challenge in liver disease patients. To overcome the scarcity of donor livers, hepatocytes generated from embryonic stem cell or induced pluripotent stem cell differentiation cultures could provide an unlimited supply of such cells for transplantation. This review provides an updated summary of hepatic differentiation protocols published so far, with a characterization of the hepatic cells generated and their ability to regenerate damaged livers following transplantation in pre-clinical liver deficient mouse models.
肝脏疾病影响着全球数百万人,尤其是在发展中国家。根据美国肝脏基金会的数据,每10个美国人中就有近1人患有某种形式的肝脏疾病。尽管肝脏具有很强的自我修复能力,但在包括纤维化、肝硬化以及由病毒性肝炎和药物引起的肝癌等终末期肝脏疾病中,肝脏的再生能力已耗尽。慢性肝衰竭唯一成功的治疗方法是全肝移植。最近,一些使用肝细胞移植的临床试验已显示出对代谢性肝病和急性肝衰竭有一定的临床改善。然而,供体肝脏的短缺仍然是肝病患者面临的危及生命的挑战。为了克服供体肝脏的稀缺问题,从胚胎干细胞或诱导多能干细胞分化培养物中产生的肝细胞可为移植提供无限量的此类细胞。本综述提供了迄今为止已发表的肝脏分化方案的最新总结,以及对所产生的肝细胞的特征描述,及其在临床前肝脏缺陷小鼠模型中移植后再生受损肝脏的能力。